Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression

Oncotarget

Volumn 4, Issue 2, 2013, Pages 269-276

  Delto, Joan C ^a   Kobayashi, Takashi ^a   Benson, Mitchell ^a   McKiernan, James ^a   Abate Shen, Cory ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; BLADDER WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CARCINOMA IN SITU; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MONOTHERAPY; MOUSE; NONHUMAN; ORGAN WEIGHT; TUMOR VOLUME;

EID: 84875787778     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.852     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urologic oncology. 2010;28:409-28.
3. McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, et al. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urologic oncology. 2010;28:429-40.
4. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, et al. Focus on bladder cancer. Cancer cell. 2004;6:111-6.
5. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urologic oncology. 2010;28:401-8.
6. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239-49.
7. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapyplus cystectomy compared with cystectomy alone for locally advanced bladder cancer. The New England journal of medicine. 2003;349:859-66.
8. Sternberg CN. Muscle invasive and metastatic bladder cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2006;17 Suppl 10:x23-30.
9. Parekh DJ, Bochner BH, Dalbagni G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24:5519-27.
10. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. The Journal of urology. 2007;178:2314-30.
11. Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 2009;3:S199- 205.
12. McKiernan JM, Masson P, Murphy AM, Goetzl M, Olsson CA, Petrylak DP, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24:3075-80.
13. Laudano MA, Barlow LJ, Murphy AM, Petrylak DP, Desai M, Benson MC, et al. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology. 2010;75:134-7.
14. Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24:2729-34.
15. Laufer M, Ramalingam S, Schoenberg MP, Haisfield-Wolf ME, Zuhowski EG, Trueheart IN, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21:697-703.
16. Witjes JA, van der Heijden AG, Vriesema JL, Peters GJ, Laan A, Schalken JA. Intravesical gemcitabine: a phase 1 and pharmacokinetic study. European urology. 2004;45:182-6.
17. Hadaschik BA, Black PC, Sea JC, Metwalli AR, Fazli L, Dinney CP, et al. A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU international. 2007;100:1377-84.
18. Hadaschik BA, ter Borg MG, Jackson J, Sowery RD, So AI, Burt HM, et al. Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer. BJU international. 2008;101:1347-55.
19. Dumez H, Martens M, Selleslach J, Guetens G, De Boeck G, Aerts R, et al. Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study. Anti-cancer drugs. 2007;18:211-8.
20. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989;64:2448-58.
21. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes & development. 2009;23:675-80.
22. Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, Mc Kiernan J, et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila). 2009;2:1008-14.
23. Brocks CP, Buttner H, Bohle A. Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer. The Journal of urology. 2005;174:1115-8.
24. Mugabe C, Matsui Y, So AI, Gleave ME, Heller M, Zeisser-Labouebe M, et al. In vitro and in vivo evaluation of intravesical docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols in an orthotopic model of bladder cancer. Biomacromolecules. 2011;12:949-60.
25. Nativ O, Dalal E, Laufer M, Sabo E, Aronson M. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer. Urology. 2004;64:845-8.
26. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. The Journal of clinical investigation. 2008;118:3051-64.